Navigation Links
A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
Date:10/14/2009

CHICAGO, Oct. 14 /PRNewswire/ -- ValenTx, Inc. announces the presentation of the first clinical study of their endoluminal approach for the treatment of morbid obesity at the 2009 American College of Surgeons Clinical Congress. The ValenTx procedure is enabled by an implantable and removable sleeve that mimics the mechanisms of gastric bypass surgery without the risks associated with that procedure.

In a collaborative study led by physicians from the University of California San Diego Medical Center and the Imperial College of London, and conducted at the Hospital San Jose de Monterrey in Monterrey, Mexico, 12 patients underwent the implantation of the ValenTx bypass sleeve during a 12-week trial. Patients completing the study achieved an average excess weight loss of 39.5%.

"I'm very excited to present this work at the American College of Surgeons Clinical Congress," said Dr. Bryan J. Sandler, co-author on the study and presenter of the scientific paper. "This initial trial indicates that we can significantly reduce excess weight and positively impact the co-morbidities commonly seen in this patient population."

"We are very honored that the study of our device has been chosen for presentation at the ACS meeting," said James Wright, President of ValenTx. "We see the selection as an affirmation of our clinical focus: to develop a device with the proven therapy mechanisms of a highly effective bariatric procedure, but to enable this in a safer, less invasive manner."

In addition to an oral presentation of the study at the ACS Congress, a video presentation was accepted for the prestigious event. The clinical study will also be published in the Journal of the American College of Surgeons.

"This is very promising data," said Santiago Horgan, M.D., Director of UCSD's Center for the Treatment of Obesity and lead author on the study. "Furthermore, our experience with this device reveals the potential for a completely incision-less and reversible, outpatient procedure in the future."

The study concluded that the ValenTx device could be safely implanted and removed in all patients. In addition to achieving significant weight loss, diabetic patients in the study maintained normal fasting blood glucose levels, without anti hyperglycemic medications during the trial.

About ValenTx

ValenTx, Inc. is developing a less-invasive, implantable medical device to address morbid obesity. The Company's founding principle was to emulate the proven mechanisms of gastric bypass surgery, but with a less invasive, implantable, and removable device. ValenTx was initially funded by leading medical technology venture capital investors, Sapient Capital, EDF Ventures, Kaiser Permanente, Affinity Capital Partners, and T-Gap Ventures. A recent fundraising was led by SV Life Sciences and also included Covidien Ventures. ValenTx is based in Carpinteria, California.

SOURCE ValenTx, Inc.


'/>"/>
SOURCE ValenTx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
2. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
3. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
4. Unique Hearing Aid Receives Patent Protection
5. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
6. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
7. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
8. Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data
9. Music & Medicine: Unique Collaboration Combines Performing Arts and Science
10. Bionovos Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
11. National Cancer Institute Research Identifies Unique Mechanism of Brostallicins Anti-Tumor Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Feb. 23, 2017 Visiomed, the French ... since 1997, is changing the landscape of healthcare ... patients with pro-active, custom-made solutions. Recognizing the rising ... and affordable healthcare without walls, Visiomed has launched ... developed with healthcare professionals that is empowering the ...
(Date:2/23/2017)... SEOUL , Südkorea, 23. Februar 2017 ... LED für Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache ... kurzwellige ultraviolette Strahlung im Bereich zwischen 200 und 280 nm ... Ausbreitung von Bakterien, indem es ihre DNA zerstört. Das ... 280 nm. ...
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... , ... Current Meditation , a new meditation concept ... U.S. starting this spring. Current Meditation focuses on “meditation for the modern world,” ... will be the first meditation concept in the U.S. offering franchising opportunities, setting ...
(Date:2/23/2017)... ... (PRWEB) ... opportunity for the nation to come together to combine its ... – with its favorite fruit – apples! To celebrate National ... to join the “Apple Madness” bracket tournament – a five-week, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today that the Blüm ... in children aged 3-8 with Autism, is now enrolling at three new sites. These ... the United States. , “There are currently no approved drugs that address the ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez has lived ... continued to spiritually evolve, which is the purpose of everyone in this universe. As ... ” (published by Balboa Press) attempts to guide readers to expand one’s spiritual life. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Gevir, a New Zealand-based company that ... its products are coming soon to Amazon.com, the world’s largest online retailer. ... means to develop an effective natural treatment for Shelley’s Multiple Sclerosis, which she’d been ...
Breaking Medicine News(10 mins):